Envista (NYSE:NVST) Shares Down 2.1%

Envista Holdings Co. (NYSE:NVST)’s share price fell 2.1% during mid-day trading on Friday . The stock traded as low as $16.34 and last traded at $16.39. 62,270 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 2,368,608 shares. The stock had previously closed at $16.74.

Analyst Ratings Changes

Several research firms have issued reports on NVST. Evercore ISI decreased their price target on shares of Envista from $24.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 25th. Morgan Stanley lowered shares of Envista from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $33.00 to $21.00 in a research note on Friday, April 26th. The Goldman Sachs Group cut their target price on shares of Envista from $20.00 to $17.50 and set a “sell” rating on the stock in a research note on Friday, May 3rd. Robert W. Baird cut their target price on shares of Envista from $22.00 to $19.00 and set a “neutral” rating on the stock in a research note on Thursday, May 2nd. Finally, JPMorgan Chase & Co. cut their target price on shares of Envista from $29.00 to $23.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $22.85.

Envista Price Performance

The stock has a market capitalization of $2.73 billion, a P/E ratio of -22.00, a PEG ratio of 13.21 and a beta of 1.31. The stock’s fifty day moving average is $17.80 and its 200-day moving average is $20.61. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.27 and a quick ratio of 1.93.

Envista (NYSE:NVST) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $0.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.05). The business had revenue of $623.60 million during the quarter, compared to the consensus estimate of $634.85 million. Envista had a positive return on equity of 5.84% and a negative net margin of 4.70%. The company’s revenue for the quarter was down .6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.38 earnings per share. On average, equities analysts anticipate that Envista Holdings Co. will post 1.2 earnings per share for the current year.

Institutional Investors Weigh In On Envista

Large investors have recently bought and sold shares of the business. Headinvest LLC acquired a new position in Envista during the 3rd quarter worth $28,000. Fifth Third Bancorp lifted its position in Envista by 98.1% during the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock worth $30,000 after acquiring an additional 621 shares during the last quarter. Versant Capital Management Inc lifted its position in Envista by 1,420.3% during the 2nd quarter. Versant Capital Management Inc now owns 3,147 shares of the company’s stock worth $52,000 after acquiring an additional 2,940 shares during the last quarter. Signaturefd LLC lifted its position in Envista by 1,297.9% during the 4th quarter. Signaturefd LLC now owns 2,614 shares of the company’s stock worth $63,000 after acquiring an additional 2,427 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its position in Envista by 538.0% during the 4th quarter. Quadrant Capital Group LLC now owns 3,209 shares of the company’s stock worth $77,000 after acquiring an additional 2,706 shares during the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.